A huge congratulations to TLI Investigator Ashraf S. Ibrahim, PhD! Dr. Ibrahim (@IbrahimLab3) has been elected by the Infectious Diseases Society of America (@IDSAInfo) as a Fellow. This prestigious #fellowship reflects Dr. Ibrahim's professional excellence and his dedication to advancing the field of #infectiousdiseases. Read more: idsociety.org/news--publicat…

Innovation begins with a bold idea, but it takes believers to bring it to life. 🔬 At The Lundquist Institute, scientists like Ashraf Ibrahim, PhD are turning ideas into discoveries. In this video, @IbrahimLab3 shares what innovation means to him and how TLI is fueling innovation and entrepreneurship. Behind every discovery is a community of supporters who believe in the work that we do. Right now through June 30, for every dollar you give, TLI’s Board of Directors will give a dollar to the Institute’s Greatest Needs until $70,000 in matching funds are exhausted. Make your gift today and help shorten the distance between discovery and cure. Visit Lundquist.org/donate. #BiomedicalResearch #Innovation #Philanthropy #MedicalResearch #TranslationalResearch #HealthcareInnovation #ScienceForGood

New research has identified albumin — the most abundant protein in human blood — as a powerful natural defense against mucormycosis, a rare but often deadly fungal infection. 🧫 “This is a remarkable finding and has the potential to change the way clinicians care for mucormycosis,” said TLI Investigator @IbrahimLab3, senior author of the study published in @Nature. The discovery opens promising pathways for albumin-based therapies and targeted immunotherapies, offering hope for patients facing this often-fatal disease. Read the full story: bit.ly/4r9Ckcl #MedicalBreakthrough #MedicalFindings #InfectiousDisease #BiomedicalResearch #Mucormycosis #GlobalHealth #PublicHealth #ScientificDiscovery

The Lundquist Institute, together with its start-up company @VitalexBioscien, is proud to announce a significant advancement in fungal vaccine research.🔬 Supported by a highly competitive $40 million contract from the NIH’s @NIAIDNews, the team is moving its second-generation, dual-antigen vaccine candidate VXV-01 into Phase 1 clinical trials. "It is the culmination of years of work on our TLI technology platform and reflects our commitment to tackling high-impact infectious disease challenges," said Ashraf Ibrahim, PhD, TLI Investigator, VXV-01 Program Lead, and CEO of Vitalex Biosciences. Learn more about this breakthrough: bit.ly/48cBJA4 #FungalInfections #VaccineResearch #BiomedicalInnovation #InfectiousDiseases #ClinicalTrials #TranslationalScience #ScientificDiscovery #HealthInnovation

IT'S A TWO-FER! A huge congratulations to TLI Investigator @IbrahimLab3 for receiving the 43rd Kuwait Prize by the @KuwaitFAS. This prestigious award honors Kuwaiti and Arab scientists for their exceptional scientific and intellectual contributions on a global scale.🚀 Dr. Ibrahim was also awarded by @NIAIDNews with a multi-year NIH grant exceeding $11 Million to transform the diagnosis and treatment of the deadly #Mucormycosis.🔬 "This investment from NIAID validates two decades of collaborative research and positions us to finally outpace a disease that currently kills at least half of the patients it strikes," said Dr. Ibrahim. Read more: bit.ly/4eTPUf8 #innovation #medicalresearch #sciencenews

Mucormycosis is a fungal infection that causes severe disease and fatality, especially in immunocompromised individuals. While vaccines and immunotherapeutics have been available in combating viral and bacterial infections, approved antifungal immunotherapies are lacking. Thanks to @IbrahimLab3 and their team's #research published on @ScienceMagazine, we are advancing towards increasing the efficiency of current treatment options for Mucormycosis to improve patient outcomes — a major translational step. #medicalresearch #biomedicine #sciencetranslationalmedicine #immunotherapy

Mucormycosis is a fungal infection that causes severe disease and fatality. “Mucormycosis usually occurs in patients who suffer from weakened immune system, such as patients with poorly controlled diabetes, cancer patients undergoing chemotherapy, and transplant patients,” says TLI Investigator Ashraf Ibrahim, PhD. 🔬🧪 Learn more about the groundbreaking antibody Dr. Ashraf Ibrahim, Dr. Yiyou Gu, and the @IbrahimLab3 team has developed that could be a promising treatment to help fight mucormycosis: bit.ly/4iHC8x0 #medicalresearch #biomedicine #Immunotherapy #publications

🔬✨ National Immunization Awareness Month✨🔬 This August, we spotlight the critical role of vaccines and immunotherapies in our fight against infectious diseases. Learn more about @IbrahimLab3's work and @the_lundquist below: instagram.com/p/C-6AZhTyhd8/…

@the_lundquist Investigator Ashraf Ibrahim, PhD, has been selected by the Medical Mycology Society of the Americas (MMSA) to receive the 2024 Billy H. Cooper Award for his continuous outstanding achievement in clinical mycology. TLI congratulates Dr Ibrahim for this high honor.